Valneva starts PhII C. diff trial; EC backs Ebola vaccine consortium for GSK candidate;

> Valneva has kicked off a Phase II trial of its Clostridium difficile vaccine. Report

> The European Commission (EC) has put €15.1 million behind a consortium of leading research institutions devoted to advancing development of GlaxoSmithKline's Ebola vaccine candidate. More

> Seattle researchers have discovered a vaccine candidate that they expect to stimulate the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains. Release

> The U.S. Patent and Trademark Office has issued key protection for ImmunoCellular Therapeutics' glioblastoma vaccine. Release

And Finally... A mumps outbreak that has so far affected 15 NHL players on 5 teams "could happen anywhere," experts say. More

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.